

List of Figures

Figure No.	Description	Page No.
Figure 1.1	Stages of <i>Mycobacterium tuberculosis</i> infection	1
Figure 1.2	First line anti-TB drugs	2
Figure 1.3	Second line anti-TB drugs	3
Figure 1.4	Morphological variations in MTB. (A) Thin section transmission electron micrograph of MTB (extracted from www.wadsworth.org/databank/mycotubr.htm); (B) Scanning electron microscope shows shape variation in MTB at exponential phase of growth	6
Figure 1.5	The mycobacterial cell wall	9
Figure 1.6	Fatty acid/mycolic acid biosynthesis in mycobacteria	11
Figure 1.7	Effectiveness and tolerability relation of first- line and second-line drugs used in TB treatment	18
Figure 1.8	Cell wall synthesis inhibitors	19
Figure 1.9	Mechanism of action of existing drugs/new anti-tubercular drugs in development	26
Figure 1.10	Various agents that are currently being investigated for TB therapy	27
Figure 1.11	Structure of anti-TB agents under preclinical development	28
Figure 1.12	Structure of anti-TB agents under phase-I & II clinical trials	31
Figure 1.13	Structure of anti-TB agents under phase-III clinical trials	37
Figure 1.14	FQ drugs were obtained using bioisosteric replacement	42
Figure 1.15	Chemical structure of linezolid bioisosteric derivatives	43
Figure 1.16	Different hybrid compounds obtained by molecular hybridization.	44
Figure 1.17	Molecular hybridization between FQ and INH	45
Figure 1.18	Quinoxaline-1,4-di- <i>N</i> -oxide molecular hybridization with INH	45
Figure 3.1	Pyrazole based drugs	55
Figure 3.2	Some of the pyrazole based anti-tubercular agents	56
Figure 3.3	Some of the triazole based anti-tubercular agents	57

Figure No.	Description	Page No.
Figure 3.4	Structures of literature reported MTB PS inhibitors	58
Figure 3.5	Design strategy of the title compounds	59
Figure 3.6	Superimposed view of co-crystallized ligand (green) with its X-ray pose (red) in 3IUB	64
Figure 3.7	Docked pose of compound 7d inside the 3IUB, showing two-dimensional interactive diagram	65
Figure 3.8	ORTEP diagram showing the X-ray crystal structure of the compound 7g with a methanol solvent of crystallization	67
Figure 4.1	Fluorenone containing natural products and semi synthetic compounds	88
Figure 4.2	InhA inhibitors	90
Figure 4.3	Anti-TB activity of triazole	92
Figure 4.4	Design strategy to achieve title compounds	93
Figure 4.5	Superimposed view of co-crystallized ligand in 1BVR	101
Figure 4.6	Docked pose of compound 17f inside the 1BVR, showing two-dimensional interactive diagram	102
Figure 4.7	Docked pose of compound 17p inside the 1BVR, showing two-dimensional interactive diagram	102
Figure 4.8	Cytotoxicity assay of 12p, 15e, 15f, 15g, 15q & 17p on HEK-293 cells	104
Figure 4.9	ORTEP diagram showing the X-ray crystal structure of the compound 15a	106
Figure 4.10	ORTEP diagram showing the X-ray crystal structure of the compound 15r	107
Figure 5.1	Some of the 1,2,4 triazole based anti-tubercular agents	135
Figure 5.2	Some of the tetrazole based anti-tubercular agents	136
Figure 5.3	Some of the sulfonamide based anti-tubercular agents	137
Figure 5.4	Design strategy to achieve title compounds	138
Figure 6.1	Some of the <i>N</i> -oxide based anti-tubercular agents	167
Figure 6.2	Some of the triazole based anti-tubercular agents	168
Figure 6.3	Design strategy of the title compounds	169
Figure 6.4	Cytotoxicity assay of 36, 36e, 36f, 36i, 36l, 37b , 37c & 37d on HEK-293 cells	174
Figure 7.1	Most active compounds structures of synthesized compounds	194



This document was created with the Win2PDF "print to PDF" printer available at <http://www.win2pdf.com>

This version of Win2PDF 10 is for evaluation and non-commercial use only.

This page will not be added after purchasing Win2PDF.

<http://www.win2pdf.com/purchase/>